Effects of the cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) on the physiology of cultured human keratinocytes

Biochemical Pharmacology

Volumn 70, Issue 6, 2005, Pages 824-836

  Atanasova, Ganka ^a,b   Jans, Ralph ^a   Zhelev, Nikolai ^c   Mitev, Vanio ^b   Poumay, Yves ^a  

^a UNIVERSITY OF NAMUR   (Belgium)

^b MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

^c UNIVERSITY OF ABERTAY DUNDEE   (United Kingdom)

Author keywords

Cell cycle inhibition; Gene expression; Involucrin; Keratinocytes; p38 Signaling; Roscovitine

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 NITROPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; CASPASE 3; CYCLIN DEPENDENT KINASE INHIBITOR; HEAT SHOCK PROTEIN 27; INVOLUCRIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; ROSCOVITINE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; CANCER CELL; CELL DENSITY; CELL LOSS; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG INHIBITION; DRUG POTENCY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME SUBSTRATE; EPIDERMIS CELL; HUMAN; HUMAN CELL; KERATINOCYTE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION;

APOPTOSIS; CELLS, CULTURED; CYCLIN-DEPENDENT KINASES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; ENZYME INHIBITORS; EPIDERMIS; HEAT-SHOCK PROTEINS; HUMANS; KERATINOCYTES; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PURINES; SIGNAL TRANSDUCTION;

EID: 23744484474     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2005.06.005     Document Type: Article

References (42)

1. I.A. McKay, and I.M. Leigh Altered keratinocyte growth and differentiation in psoriasis Clin Dermatol 13 1995 105 114
2. P.C. Van de Kerkhof, and P.E. Van Erp The role of epidermal proliferation in the pathogenesis of psoriasis Skin Pharmacol 9 1996 343 354
3. L. Meijer Chemical inhibitors of cyclin-dependent kinases Trends Cell Biol 6 1996 393 397
4. P.M. Fischer, and A. Gianella-Borradori CDK inhibitors in clinical development for the treatment of cancer Expert Opin Investig Drugs 12 2003 955 970
5. M. Knockaert, P. Greengard, and L. Meijer Pharmacological inhibitors of cyclin-dependent kinases Trends Pharmacol Sci 23 2002 417 425
6. S.J. McClue, D. Blake, R. Clarke, A. Cowan, L. Cummings, and P.M. Fisher In vitro and in vivo antitumor properties of the cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) Int J Cancer 102 2002 463 468
7. L. Meijer, A. Borgne, O. Mulner, J.P. Chong, J.J. Blow, and N. Inagaki Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5 Eur J Biochem 243 1997 527 536
8. F. Alessi, S. Quarta, M. Savio, F. Riva, L. Rossi, and L.A. Stivala The cyclin-dependent kinase inhibitors olomoucine and roscovitine arrest human fibroblasts in G1 phase by specific inhibition of CDK2 kinase activity Exp Cell Res 245 1998 8 18
9. O.P. Mgbonyebi, J. Russo, and I.H. Russo Roscovitine induces cell death and morphological changes indicative of apoptosis in MDA-MB-231 breast cancer cells Cancer Res 15 1999 1903 1910
10. L. Meijer, and E. Raymond Roscovitine and other purines as kinase inhibitors: from starfish oocytes to clinical trials Acc Chem Res 36 2003 417 425
11. P.W. Cook, M.R. Pittelkow, and G.D. Shipley Growth factor-independent proliferation of normal human neonatal keratinocytes: production of autocrine- and paracrine-acting mitogenic factors J Cell Physiol 146 1991 277 289
12. Y. Poumay, and M.R. Pittelkow Cell density and culture factors regulate keratinocyte commitment to differentiation and expression of suprabasal K1/K10 keratins J Invest Dermatol 104 1995 271 276
13. O.J. Lowry, N.J. Rosebrough, A.L. Farr, and R.J. Randall Protein measurements with Folin phenol reagent J Biol Chem 193 1951 265 275
14. M. Schwab, K. Alitalo, H.E. Varmus, J.M. Bishop, and D. George A cellular oncogene (c-Ki-ras) is amplified, over expressed and located with karyotypic abnormalities in mouse adrenocortical tumor cells Nature 303 1983 497 501
15. I.Y. De Potter, Y. Poumay, K.A. Squillace, and M.R. Pittelkow Human EGF receptor (HER) family and heregulin members are differentially expressed in epidermal keratinocytes and modulate differentiation Exp Cell Res 271 2001 315 328
16. J. Laborda 36B4 cDNA used as an estradiol-independent mRNA control is the cDNA for human acidic ribosomal phosphoprotein PO Nucleic Acids Res 19 1991 3998
17. S.W. Stoll, S. Kansra, S. Peshick, D.W. Fry, W.R. Leopold, and J.F. Wielsen Differential utilization and localization of ErbB receptor tyrosine kinases in skin compared to normal and malignant keratinocytes Neoplasia 3 2001 339 350
18. J.J. Wille Jr., M.R. Pittelkow, G.D. Shirpley, and R.E. Scott Integrated control of growth and differentiation of normal human prokeratinocytes cultured in serum free medium: clonal analyses, growth kinetics and cell cycle studies J Cell Physiol 121 1984 31 44
19. M. Ljungman, and M.T. Paulsen The cyclin-dependent kinase inhibitor roscovitine inhibits RNA synthesis and triggers nuclear accumulation of p53 that is unmodified at Ser15 and Lys382 Mol Pharmacol 60 4 2001 785 789
20. S.R. Whittaker, M.I. Walton, M.D. Garrett, and P. Workman The cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of cyclin D1, and activates the mitogen-activated protein kinase pathway Cancer Res 64 2004 262 272
21. R.L. Eckert, T. Efimova, S.R. Dashti, S. Balasubramanian, A. Deucher, and J.F. Crish Keratinocyte survival, differentiation, and death: many roads lead to mitogen-activated protein kinase J Investig Dermatol Symp Proc 7 1 2002 36 40
22. V. Mitev, and L. Miteva Signal transduction in keratinocytes Exp Dermatol 2 1999 96 108
23. M. Praskova, S. Kalenderova, L. Miteva, Y. Poumay, and V. Mitev Dual role of protein kinase C on mitogen-activated protein kinase activation and human keratinocyte proliferation Exp Dermatol 11 4 2002 344 348
24. V. Mitev, R. Le Panse, B. Coulomb, L. Miteva, and L.M. Houdebine Epidermal growth factor stimulates mitogen-activated protein kinase by a PKC-dependent pathway in human keratinocytes Biochem Biophys Res Commun 208 1 1995 245 252
25. R.L. Eckert, T. Efimova, S. Balasubramanian, J.F. Crish, F. Bone, and S. Dashti p38 Mitogen-activated protein kinase on the body surface: function for p38 delta J Invest Dermatol 120 2003 823 828
26. K. Deacon, P. Mistry, J. Chernoff, J.L. Blank, and R. Patel p38 Mitogen-activated protein kinase mediates cell death and p21-activated kinase mediates cell survival during chemotherapeutic drug-induced mitotic arrest Mol Biol Cell 14 2003 2071 2087
27. T. Efimova, A.M. Broome, and R.L. Eckert A regulating role for p38 delta MAPK in keratinocyte differentiation: evidence for p38 delta-RK1/2 complex formation J Biol Chem 278 36 2003 34277 34285
28. R. Jans, G. Atanasova, M. Jadot, and Y. Poumay Cholesterol depletion upregulates involucrin expression in epidermal keratinocytes through activation of p38 J Invest Dermatol 123 3 2004 564 573
29. M. Garmyn, T. Mammone, A. Pupe, D. Gan, L. Declercq, and D. Maes Human keratinocytes respond to osmotic stress by p38 map kinase regulated induction of HSP70 and HSP27 J Invest Dermatol 117 2001 1290 1295
30. J. Guay, H. Lambert, G. Gingras-Breton, J. Lavoie, J. Huot, and J. Landry Regulation of actin dinamics by p38 map kinase-mediated phosphorylation of heat shock protein 27 J Cell Sci 110 1997 357 368
31. M. Niwa, K. Hotta, Y. Kanamori, D. Hatakeyama, K. Hirade, and M. Katayama Involvement of p38 mitogen-activated protein kinase in heat shock protein 27 induction in human neutrophils Eur J Pharmacol 466 2003 245 253
32. J.W. Wong, B. Shi, B. Farboud, M. McClaren, T. Shubamoto, and C.E. Cross Ultraviolet B-mediated phosphorylation of the heat shock protein HSP27 in human keratinocytes J Invest Dermatol 115 3 2000 427 434
33. C. Missero, E. Calautti, R. Eckner, J. Chin, H.T. Li, and D.M. Livingston Involvement of the cell-cycle inhibitor Cip1/WAF1 and the E1A-associated p300 protein in terminal differentiation Proc Natl Acad Sci 92 1995 5451 5455
34. B. Malgrange, M. Knockaert, S. Belachew, L. Nguyen, G. Moonen, and L. Meijer The inhibition of cyclin-dependent kinases induces differentiation of supernumerary hair cells and Deiters' cells in the developing organ of Corti FASEB J 17 14 2003 2136 2138
35. Y.N. Chen, S. Sharma, T. Ramsey, L. Jiang, M.S. Martin, and K. Baker Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists Proc Natl Acad Sci 96 1999 4325 4329
36. J. Wesierska-Gadek, M. Gueorguieva, and M. Horky Dual action of cyclin-dependent kinase inhibitors: induction of cell cycle arrest and apoptosis: a comparison of the effects exerted by roscovitine and cisplatin Pol J Pharm 55 2003 895 902
37. E. Verdaguer, E. Jorda, A. Canudas, A. Jimenez, D. Pubill, and E. Escubedo Antiapoptotic effects of roscovitine in cerebellar granule cells deprived of serum and potassium: a cell cycle-related mechanism Neurochem Int 44 2004 251 261
38. H. Zhang, X. Shi, M. Hampong, L. Blanis, and S. Pelech Stress-induced inhibition of ERK1 and ERK2 by direct interaction with p38 MAP kinase J Biol Chem 276 2001 6905 6908
39. A.J. Alvi, B. Austen, V.J. Weston, C. Fegan, D. Maccallum, and A. Gianella-Borradori A novel CDK inhibitor, CYC (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by downregulation of genes involved in transcription regulation and survival Blood 105 11 2005 4484 4491
40. T. Zarubin, and J. Han Activation and signalling of the p38 MAP kinase pathway Cell Res 15 1 2005 11 18
41. 2-terminal kinase and p38 kinase in calphostin C-induced apoptosis requires caspase-3-like proteases but is dispensable for cell death J Biol Chem 274 9 1999 5310 5317
42. S.R. Lee, and E.H. Lo Interactions between p38 mitogen-activated protein kinase and caspase-3 in cerebral endothelial cell death after hypoxia-reoxygenation Stroke 34 11 2003 2704 2709